FDA Allows Broader Access to Experimental Pancreatic Cancer Drug

The U.S. Food and Drug Administration has approved an expanded access protocol for daraxonrasib, an investigational drug for metastatic pancreatic cancer. This decision, often referred to as compassionate use, allows patients with no other treatment options to access the experimental medication. Clinical trials have shown promising efficacy, with the drug nearly doubling the average survival time for this patient population. The swift approval highlights the agency's commitment to facilitating early access for serious and life-threatening conditions.